Personnel Information

写真a

YAMAMOTO Masahide


Job title

Junior Associate Professor

Mail Address

The inquiry by e-mail is 《here》
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2009.04
    -
    2018.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2018.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Junior Associate Professor
To the head of this page.▲

Academic Society Affiliations 【 display / non-display 】

  • Japanese Society of Hematology

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Akiyama M, Kanayama M, Umezawa Y, Nagao T, Izumi Y, Yamamoto M, Ohteki T. An early regulatory mechanism of hyperinflammation by restricting monocyte contribution. Frontiers in immunology. 2024.07; 15 1398153. ( PubMed, DOI )

  2. Umezawa Y, Yoshifuji K, Tanaka K, Nogami A, Nagano K, Tsuji A, Nagao T, Yamamoto M, Kajiwara M, Tohda S, Mori T. Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation. Annals of hematology. 2024.05; 103 (5): 1737-1744. ( PubMed, DOI )

  3. Kawade G, Kurata M, Matsuki Y, Fukuda S, Onishi I, Kinowaki Y, Watabe S, Ishibashi S, Ikeda M, Yamamoto M, Ohashi K, Kitagawa M, Yamamoto K. Mediation of FSP1 expression via 4-HNE accumulation contributes to acquisition of resistance to apoptosis and ferroptosis in DLBCL. Laboratory investigation; a journal of technical methods and pathology. 2024.02; 102027. ( PubMed, DOI )

  4. Hikaru Aoki, Yasunari Miyazaki, Tatsuhiko Anzai, Kota Yokoyama, Junichi Tsuchiya, Tsuyoshi Shirai, Sho Shibata, Rie Sakakibara, Takahiro Mitsumura, Takayuki Honda, Haruhiko Furusawa, Tsukasa Okamoto, Tomoya Tateishi, Meiyo Tamaoka, Masahide Yamamoto, Kunihiko Takahashi, Ukihide Tateishi, Tetsuo Yamaguchi. Deep convolutional neural network for differentiating between sarcoidosis and lymphoma based on [18F]FDG maximum-intensity projection images Eur Radiol. 2024.01; 34 (1): 374-383. ( PubMed, DOI )

  5. Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT. Ann Hematol. 2024.01; 103 (1): 307-320. ( PubMed, DOI )

  6. Motomura, Y; Yoshifuji, K; Tachibana, T; Takase, H; Arai, A; Tanaka, K; Okada, K; Nogami, A; Umezawa, Y; Sakashita, C; Yamamoto, M; Mori, T; Nagao, T. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma BRITISH JOURNAL OF HAEMATOLOGY. 2023.12; ( PubMed, DOI )

  7. Keisuke Tanaka, Ayako Ichikawa, Natsuka Umezawa, Kouhei Yamamoto, Kota Yoshifuji, Keigo Okada, Ayako Nogami, Yoshihiro Umezawa, Toshikage Nagao, Chizuko Sakashita, Takehiko Mori, Shuji Tohda, Ryuji Koike, Shinsuke Yasuda, Masahide Yamamoto. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023.09; 114 (9): 3719-3727. ( PubMed, DOI )

  8. Masahide Yamamoto, Maho Sato, Yasushi Onishi, Yoji Sasahara, Hideki Sano, Masayoshi Masuko, Hirohisa Nakamae, Ken-Ichi Matsuoka, Takahide Ara, Kana Washio, Makoto Onizuka, Kenichiro Watanabe, Yoshiyuki Takahashi, Tsuneaki Hirakawa, Miwako Nishio, Chizuko Sakashita, Tohru Kobayashi, Akihisa Sawada, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Hashii, Yoshiko Atsuta, Ayako Arai. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022.06; 97 (6): 780-790. ( PubMed, DOI )

  9. Tsuyoshi Nakagawa, Kumiko Hayashi, Ayumi Ogawa, Goshi Oda, Iichiro Onishi, Masahide Yamamoto, Mio Mori, Tomoyuki Fujioka, Toshiaki Ishikawa, Kentaro Okamoto, Hiroyuki Uetake. Bone Marrow Carcinomatosis in a Stage IV Breast Cancer Patient Treated by Letrozole as First-Line Endocrine Therapy. Case Rep Oncol. 2022.04; 15 (1): 436-441. ( PubMed, DOI )

  10. Hirohisa Nakamae, Masahide Yamamoto, Emiko Sakaida, Yoshinobu Kanda, Ken Ohmine, Takaaki Ono, Itaru Matsumura, Maho Ishikawa, Makoto Aoki, Akio Maki, Hirohiko Shibayama. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022.01; 115 (1): 33-42. ( PubMed, DOI )

  11. Yuji Sekine, Kouhei Yamamoto, Morito Kurata, Ayaka Honda, Iichiroh Onishi, Yuko Kinowaki, Genji Kawade, Shiori Watabe, Serina Nomura, Sho Fukuda, Sachiko Ishibashi, Masumi Ikeda, Masahide Yamamoto, Masanobu Kitagawa. HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma. Pathology. 2021.09; (21): 435-439. ( PubMed, DOI )

  12. Masayuki Nagasawa, Noriko Mitsuiki, Masakatsu Yanagimachi, Masahide Yamamoto, Tetsuya Fukuda, Osamu Miura, Ryutaro Oba, Akira Igarashi, Kinya Nagata, Tomohiro Morio. Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD. Int J Hematol. 2021.06; 113 (6): 910-920. ( PubMed, DOI )

  13. Yuki Fukawa, Kei Sakamoto, Takuma Kugimoto, Yasuyuki Michi, Hiroyuki Harada, Masahide Yamamoto, Masanobu Kitagawa, Tohru Ikeda, Kouhei Yamamoto. Nodular lymphocyte-predominant Hodgkin lymphoma involving the hard palate. Pathol Int. 2021.03; 71 (3): 213-215. ( PubMed, DOI )

  14. Yuta Izumi, Masashi Kanayama, Zhongchuzi Shen, Masayuki Kai, Shunsuke Kawamura, Megumi Akiyama, Masahide Yamamoto, Toshikage Nagao, Keigo Okada, Norihiko Kawamata, Shigeo Toyota, Toshiaki Ohteki. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy. Front Immunol. 2021; 12 618081. ( PubMed, DOI )

  15. Kuboki Mai, Umezawa Yoshihiro, Motomura Yotaro, Okada Keigo, Nogami Ayako, Nagao Toshikage, Miura Osamu, Yamamoto Masahide. Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment IN VIVO. 2021; 35 (6): 3407-3411. ( PubMed, DOI )

  16. Towako Taguchi, Morito Kurata, Iichiroh Onishi, Yuko Kinowako, Yunosuke Sato, Sayuri Shiono, Sachiko Ishibashi, Masumi Ikeda, Masahide Yamamoto, Masanobu Kitagawa, Kouhei Yamamoto. SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma. Lab Invest. 2020.10; ( PubMed, DOI )

  17. Ichiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, Tohru Kobayashi, Masahide Yamamoto, Akihisa Sawada, Yoshinori Ito, Noriko Fukuhara, Asao Hirose, Yusuke Takeda, Masanori Makita, Tomoyuki Endo, Shun-Ichi Kimura, Masataka Ishimura, Osamu Miura, Shouichi Ohga, Hiroshi Kimura, Shigeyoshi Fujiwara, Ayako Arai. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020.07; 4 (13): 2918-2926. ( PubMed, DOI )

  18. Shunya Matsumoto, Toshiki Kijima, Yoh Matsuoka, Masahide Yamamoto, Yasuhisa Fujii. A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab. Eur. J. Cancer. 2020.03; ( PubMed, DOI )

  19. Koji Nishikawa, Kiminori Kimura, Yoshinobu Kanda, Masaya Sugiyama, Kazuhiko Kakihana, Noriko Doki, Kazuteru Ohashi, Sung Kwan Bae, Kazuhiro Takahashi, Yuko Ishihara, Ishikazu Mizuno, Yasushi Onishi, Masahiro Onozawa, Makoto Onizuka, Masahide Yamamoto, Tetsuya Ishikawa, Kazuaki Inoue, Shigeru Kusumoto, Satoshi Hashino, Hidetsugu Saito, Tatsuya Kanto, Hisashi Sakamaki, Masashi Mizokami. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant.. 2020.02; ( PubMed, DOI )

  20. Takashi Ikeda, Keita Mori, Koji Kawamura, Takehiko Mori, Shotaro Hagiwara, Yasunori Ueda, Kaoru Kahata, Naoyuki Uchida, Nobuhiro Tsukada, Satoshi Murakami, Masahide Yamamoto, Tsutomu Takahashi, Tatsuo Ichinohe, Makoto Onizuka, Yoshiko Atsuta, Yoshinobu Kanda, Shinichiro Okamoto, Kazutaka Sunami, Hiroyuki Takamatsu. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematol Oncol. 2019.10; ( PubMed, DOI )

  21. Kota Yoshifuji, Yoshihiro Umezawa, Ayako Ichikawa, Ken Watanabe, Osamu Miura, Masahide Yamamoto. Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases. In Vivo. 2019.09; 33 (5): 1599-1604. ( PubMed, DOI )

  22. Masahide Yamamoto, Keisuke Tanaka, Yoshihiro Umezawa, Toshikage Nagao, Shigeo Toyota, Osamu Miura. Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. Anticancer Res.. 2019.09; 39 (9): 5115-5122. ( PubMed, DOI )

  23. Kouhei Yamamoto, Shinya Abe, Ayaka Honda, Jun Hashimoto, Yuuki Aizawa, Sachiko Ishibashi, Taro Takemura, Nobutaka Hanagata, Masahide Yamamoto, Osamu Miura, Morito Kurata, Masanobu Kitagawa. Fatty acid beta oxidation enzyme HADHA is a novel potential therapeutic target in malignant lymphoma. Lab. Invest.. 2019.09; ( PubMed, DOI )

  24. Keisuke Tanaka, Shigeo Toyota, Megumi Akiyama, Naoki Wakimoto, Yuichi Nakamura, Yuho Najima, Noriko Doki, Kazuhiko Kakihana, Aiko Igarashi, Takeshi Kobayashi, Kazuteru Ohashi, Daisuke Kudo, Atsushi Shinagawa, Hina Takano, Takayuki Fujio, Yasushi Okoshi, Mitsuo Hori, Takashi Kumagai, Tatsuya Saito, Junichi Mukae, Koh Yamamoto, Ikuyo Tsutsumi, Takuya Komeno, Chikashi Yoshida, Masahide Yamamoto, Hiroshi Kojima, . Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematol.. 2019.02; 141 (2): 111-118. ( PubMed, DOI )

  25. Junichi Tsuchiya, Masahide Yamamoto, Hyeyeol Bae, Takumi Oshima, Tomohiro Yoneyama, Osamu Miura, Ukihide Tateishi. Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT. Clin Nucl Med. 2019.01; ( PubMed, DOI )

  26. Makoto Nakagawa, Shuhei Fujita, Takuo Katsumoto, Kazutsune Yamagata, Yoko Ogawara, Ayuna Hattori, Yuki Kagiyama, Daisuke Honma, Kazushi Araki, Tatsuya Inoue, Ayako Kato, Koichiro Inaki, Chisa Wada, Yoshimasa Ono, Masahide Yamamoto, Osamu Miura, Yasuharu Nakashima, Issay Kitabayashi. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma. Cancer Sci.. 2019.01; 110 (1): 194-208. ( PubMed, DOI )

  27. Yuko Kinowaki, Morito Kurata, Sachiko Ishibashi, Masumi Ikeda, Anna Tatsuzawa, Masahide Yamamoto, Osamu Miura, Masanobu Kitagawa, Kouhei Yamamoto. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab. Invest.. 2018.02; ( PubMed, DOI )

  28. Masahide Yamamoto, Sayaka Suzuki, Jun-Ichi Mukae, Keisuke Tanaka, Ken Watanabe, Gaku Oshikawa, Tetsuya Fukuda, Naomi Murakami, Osamu Miura. Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. Oncol Lett. 2017.09; 14 (3): 3717-3721. ( PubMed, DOI )

  29. Keisuke Tanaka, Gaku Oshikawa, Hiroki Akiyama, Shinya Ishida, Toshikage Nagao, Masahide Yamamoto, Osamu Miura. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report. Oncol Lett. 2017.07; 14 (1): 97-102. ( PubMed, DOI )

  30. Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Yasufumi Masaki, Saburo Tsunoda, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Ohshima, Hiromichi Takahashi, Yukiyoshi Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Hideaki Nakajima, Ikuo Miura, Kengo Takeuchi. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis. Leuk. Lymphoma. 2017.06; 1-8. ( PubMed, DOI )

  31. Masahide Yamamoto, Ken Watanabe, Tetsuya Fukuda, Osamu Miura. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. Anticancer Res.. 2017.05; 37 (5): 2655-2662. ( PubMed, DOI )

  32. Koichi Miyamura, Toshihiro Miyamoto, Mitsune Tanimoto, Kazuhito Yamamoto, Shinya Kimura, Tatsuya Kawaguchi, Itaru Matsumura, Tomoko Hata, Hisashi Tsurumi, Shigeki Saito, Masayuki Hino, Seiji Tadokoro, Kuniaki Meguro, Hideo Hyodo, Masahide Yamamoto, Kohmei Kubo, Junichi Tsukada, Midori Kondo, Makoto Aoki, Hikaru Okada, Masamitsu Yanada, Kazuma Ohyashiki, Masafumi Taniwaki. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. Leuk. Res.. 2016.12; 51 11-18. ( PubMed, DOI )

  33. Hiroki Akiyama, Hiroshi Takase, Fumito Kubo, Tohru Miki, Masahide Yamamoto, Makoto Tomita, Manabu Mochizuki, Osamu Miura, Ayako Arai. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Science. 2016.10; 107 (10): 1458-1464. ( PubMed, DOI )

  34. Masahide Yamamoto, Kazuteru Ohashi, Kazuhiko Kakihana, Yuichi Nakamura, Takuya Komeno, Hiroshi Kojima, Satoshi Morita, Hisashi Sakamaki. A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. Mol Clin Oncol. 2016.06; 4 (6): 965-970. ( PubMed, DOI )

  35. Shunichiro Yasuda, Masahide Yamamoto, Tetsuya Fukuda, Yasufumi Ohtsuka, Osamu Miura. Postoperative Atypical Hemolytic Uremic Syndrome Treated Successfully with Eculizumab. Intern. Med.. 2016.05; 55 (9): 1171-1175. ( PubMed, DOI )

  36. Arai A, Sakashita C, Hirose C, Imadome K, Yamamoto M, Jinta M, Fujiwara S, Tomita M, Shimizu N, Morio T, and Miura O.. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers Bone Marrow Transplantation. 2016;

  37. Emi Uchida, Ken Watanabe, Reina Arai, Masahide Yamamoto, Masayoshi Souri, Tsukasa Osaki, Akitada Ichinose, Osamu Miura, Takatoshi Koyama. Autoimmune Hemorrhaphilia Resulting from Autoantiboy against the A Subunit of Factor XIII. Internal Medicine. 2015.09; 54 (18): 2383-2387.

  38. Masahide Yamamoto, Keigo Okada, Hiroki Akiyama, Tetsuya Kurosu, Osamu Miura. Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study. Mol Clin Oncol. 2015.03; 3 (2): 449-453. ( PubMed, DOI )

  39. Hiroki Akiyama, Masahide Yamamoto, Chizuko Sakashita, Yoshihiro Umezawa, Tetsuya Kurosu, Naomi Murakami, Osamu Miura. Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy. Intern. Med.. 2015; 54 (6): 651-655. ( PubMed, DOI )

  40. Toshikage Nagao, Tetsuya Kurosu, Yoshihiro Umezawa, Ayako Nogami, Gaku Oshikawa, Shuji Tohda, Masahide Yamamoto, Osamu Miura. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS ONE. 2014; 9 (1): e84746. ( PubMed, DOI )

  41. Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012.06; 97 (6): 903-906. ( PubMed, DOI )

  42. Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Yasufumi Masaki, Saburo Tsunoda, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Ohshima, Yoshihiro Hatta, Yukiyoshi Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Yoshiaki Ishigatsubo, Kengo Takeuchi. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci.. 2012.02; 103 (2): 245-251. ( PubMed, DOI )

  43. Masahide Yamamoto, Kazuteru Ohashi, Yuka Hirashima, Takeshi Kobayashi, Kazuhiko Kakihana, Hideki Akiyama, Hisashi Sakamaki. Poor outcome of myeloablative conditioned allogeneic bone marrow transplantation for myelofibrosis. Intern. Med.. 2012; 51 (10): 1183-1186. ( PubMed )

  44. Yamamoto M, Kakihana K, Ohashi K, Yamaguchi T, Tadokoro K, Akiyama H, Sakamaki H. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int J Hematol. 2009.05; 89 (4): 482-488. ( PubMed, DOI )

  45. Tetsuya Kurosu, Kana Tsuji, Manabu Ohki, Tohru Miki, Masahide Yamamoto, Kazuhiko Kakihana, Takatoshi Koyama, Shuichi Taniguchi, Osamu Miura. A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). Int. J. Hematol.. 2008.09; 88 (2): 192-196. ( PubMed, DOI )

  46. Kazuhiko Kakihana, Masahide Yamamoto, Mitsuko Iiyama, Osamu Miura. Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling. Biochem. Biophys. Res. Commun.. 2005.09; 335 (2): 424-431. ( PubMed, DOI )

  47. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005.03; 157 (2): 104-108. ( PubMed, DOI )

  48. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun. 2004.07; 319 (4): 1272-1275. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Norio Shimizu, Ryuji Koike,Ayako Arai. Phase II Study of a JAK1/2 Inhibitor Ruxolitinib for Systemic Chronic Active Epstein-Barr Virus Disease: An Investigator-Initiated Trial . 64th ASH Annual Meeting and Exposition 2022.12

  2. Chikashi Yoshida, Hiroki Yamaguchi, Noriko Doki, Kazunori Murai, Masaki Iino, Yoshihiro Hatta, Makoto Onizuka, Norio Yokose, Katsumichi Fujimaki, Masao Hagihara, Gaku Oshikawa, Kayoko Murayama, Takashi Kumagai, Shinya Kimura, Hideharu Muto, Kensuke Usuki, Kenji Yokoyama, Koh Yamamoto, Nobuyuki Aotsuka, Kenichi Ishizawa, Naoki Takezako, Takuto Miyagishima, Tadao Ishida, Atsushi Shinagawa, Kentaro Wakasa, Tsuyoshi Nakamaki, Naoto Tomita, Katsutoshi Ozaki, Takayoshi Itoh, Shugo Kowata, Kenji Tajika, Takayuki Fujio, Masahiro Onozawa, Masahide Yamamoto, Takeshi Kondo, Yuho Najima, Noriyoshi Iriyama, Ikuyo Tsutsumi, Koji Oba, Hiroshi Kojima, Hisashi Sakamaki, Koiti Inokuchi. Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial . 63rd ASH annual meeting and exposition 2021.12.13

  3. Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki. Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT . 63rd ASH annual meeting and exposition 2021.12.13

  4. Ayako Arai, Masahide Yamamoto, Maho Sato, Yasushi Onishi, Yoji Sasahara, Hideki Sano, Masayoshi Masuko, Hirohisa Nakamae, Ken-Ichi Matsuoka, Takahide Ara, Kana Washio, Makoto Onizuka, Kenichiro Watanabe, Tsuneaki Hirakawa, Miwako Nishio, Chizuko Sakashita, Tohru Kobayashi, Akihisa Sawada, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Hashii, Yoshiko Atsuta. The Outcomes of Systemic Chronic Active EBV Infection Treatment By Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of Japanese Registry Data. 63rd ASH annual meeting and exposition 2021.12.13

  5. Y. Minami, I. Matsumura, N. Takahashi, S. Ohtake, Y. Atsuta, M. Kurata, S. Yano, N. Iriyama, Y. Ueda, Y. Ozawa, E. Sakaida, A. Mori, M. Yamamoto, T. Ono, K. Fujimaki, C. Nakaseko, T. Miyamoto, N. Asou, H. Kiyoi, Y. Miyazaki. TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING FRONTLINE DASATINIB: RESULTS FROM JALSG D-STOP216. EHA 2021 congress virtual 2021.06.09

  6. 池田朱里、堤大樹、渡邉健、青山慧、齋藤達也、長尾俊景、坂下千瑞子、山本正英、福田哲也、東田修二、新井文子、川又紀彦、三浦修.. 二次性骨髄線維症による門脈圧亢進症性消化管出血に対してルキソリチニブが著効した一例. 日本血液学会関東甲信越地方会 2018.03.03 東京

  7. Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

  8. Ryoto Yoshimoto, Ken Watanabe, Emi Uchida, Shihoko Suwa, Shuji Tohda, Masahiko Hatano, Miura Osamu, Tetsuya Fukuda. IVNSIABP/Nd1 is highly expressed in refractory lymphoma as a novel therapeutic target molecule. The 79th Annual Meeting of the Japanese Society of Hematology 2017.10.20

  9. 渡邉健　他. Short chemotherapy prior to 90Y-ibritumomab tiuxetan for relapsed FL in a single institution.. 第77回日本血液学会学術集会 2015.10.18 石川県金沢市

  10. Emi Uchida, Shunichirou Yasuda, Ken Watanabe, Gaku Oshikawa, Masahide Yamamoto, Tetsuya Kurosu, Ayako Arai, Osamu Miura, Tetsuya Fukuda. A retrospective analysis of CLL treated with the FCR regimen.. 第77回日本血液学会学術集会 2015.10

  11. Kazuhito Yamamoto, Koich Miyamura, Toshihiro Miyamoto, Mitsune Tanimoto, Masafumi Taniwaki, Shinya Kimura, Kazuma Ohyashiki, Tatsuya Kawaguchi, Itaru Matshumura, Tomoko Hata, Hisashi Tsurumi, Shigeki Saito, Masayuki Hino, Seiji Tadokoro, Kuniaki Meguro, Hideo Hyodo, Masahide Yamamoto, Kohmei Kubo, Junichi Tsukada, Midori Kondo, Taro Amagasaki, Eiji Kawahara, Masamitsu Yanada. SENSOR INTERIM DATA WITH MUTATION ANALYSIS: SWITCHING TO NILOTINIB AFTER MOLECULAR SUBOPTIMAL RESPONSE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. 19th Congress of EHA 2014.06 Milan, Italy

▼display all

To the head of this page.▲